Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 6,096	$ 4,024
Acquired in-process research and development	0	84,478
General and administrative	4,336	3,840
Total operating expenses	10,432	92,342
Gain on Royalty Purchase Agreement	0	13,500
Loss from operations	(10,432)	(78,842)
Other income (expense)
Interest income	10	6
Interest expense	(124)	(105)
Other expense	0	(290)
Total other expense	(114)	(389)
Net loss and comprehensive loss	$ (10,546)	$ (79,231)
Net loss per share of common stock, basic and diluted	$ (0.28)	$ (5.22)
Weighted-average shares used to compute basic and diluted net loss per share	37,535,874	15,166,737